siRNA or ASOs targeting negative regulators of SOD (e.g., SOD1 mutations in ALS) aim to enhance SOD activity indirectly by silencing genes that inhibit its function [228,229]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.